Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer
Abstract Allogeneic cell-based immunotherapies, particularly CAR-T cell therapy, represent a significant advancement in cancer treatment, offering scalable and consistent alternatives to autologous therapies. However, their widespread use is limited by the risk of graft-versus-host disease (GvHD). T...
Saved in:
| Main Authors: | Zibai Lyu, Siyue Niu, Ying Fang, Yuning Chen, Yan-Ruide Li, Lili Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-025-00654-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context
by: Valentine Wang, et al.
Published: (2025-01-01) -
Editorial: Immunology of allogeneic hematopoietic stem cell transplantation
by: Carmelo Gurnari, et al.
Published: (2025-02-01) -
Soluble MHC class I chain-related protein A is a specific biomarker for the early detection of graft-versus-host disease
by: Alexander Kupis, et al.
Published: (2025-06-01) -
Extracorporeal photopheresis reduces the T cell stimulatory capacity of human primary blood conventional dendritic cells type 1
by: Lukas Heger, et al.
Published: (2025-08-01) -
A comprehensive welfare scoring system for graft versus host disease clinical assessment in humanised mouse models used for pharmaceutical research
by: Alice Nowak, et al.
Published: (2025-06-01)